Novo Nordisk A/S Sponsored ADR (NVO)
Novo Nordisk Stock Sinks To 52-Week Lows: Weight Loss Boom Losing Steam?
Novo Nordisk A/S NVO has been on a tear in the weight loss drug race, but its stock is slimming down for all the wrong reasons.
Is Novo Nordisk Stock a Buy?
There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022.
Novo Nordisk Expands Wegovy Price Cut Program, Stock Still Falls 2%
NVO's shares are down 2% despite making Wegovy available at a discounted price of $499 per month at local pharmacies.
Why Novo Nordisk Stock Dropped on Monday, but Eli Lilly and Him & Hers Health Popped
Novo Nordisk (NVO -2.06%) stock slipped 1.7% through 12:10 a.m. ET Monday on a pair of news items with which investors seem less than thrilled:
Novo Nordisk Down 15% in March: Is This a Buying Opportunity?
Despite the current downward trend of NVO, it is a good stock to add to one's portfolio for long-term gains due to strong demand for its GLP-1 drugs.
Novo Nordisk's $2 billion obesity deal
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss Eli Lilly's latest obesity pill trial.
Novo Nordisk Finds A New Way To Rival Eli Lilly. But Shares Tumble.
Novo Nordisk stock dropped Monday after the drugmaker licensed a Chinese competitor's weight-loss drug for $200 million up front. The post Novo Nordisk Finds A New Way To Rival Eli Lilly.
Novo Nordisk expands discounted Wegovy to all cash-paying US customers
Novo Nordisk said on Monday all eligible cash-paying customers in the United States can buy its weight-loss drug Wegovy at a discounted price of $499 per month at their local pharmacy.
Novo Nordisk secures license to weight-loss drug candidate from China's United Labs
China-based United Laboratories International said on Monday it will license its weight-loss drug candidate to Danish drugmaker Novo Nordisk in a deal worth up to $2 billion.
Novo Nordisk's next-gen obesity drug CagriSema had investors excited. Now they're not so sure
Novo Nordisk's latest trial results for its next-generation obesity drug CagriSema disappointed investors by failing to show superior outcomes to existing drugs. CagriSema, which includes a nascent form of weight loss treatment known as an amylin analog, is one of the Danish pharma's next bets on the burgeoning obesity market.
Why Novo Nordisk (NVO) Dipped More Than Broader Market Today
Novo Nordisk (NVO) reachead $78.79 at the closing of the latest trading day, reflecting a -0.27% change compared to its last close.
Novo Nordisk (NVO) Is Considered a Good Investment by Brokers: Is That True?
Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?
